methylprednisolone suleptanate: prodrug of methylprednisolone [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
methylprednisolone suleptanate : An organic sodium salt that is the monosodium salt of methylprednisolone 21-suleptanic acid ester. It is a prodrug of methylprednisolone developed by Pharmacia Corp for the treatment of asthma. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
ID Source | ID |
---|---|
PubMed CID | 23663977 |
CHEMBL ID | 2106453 |
CHEBI ID | 135864 |
SCHEMBL ID | 43507 |
MeSH ID | M0148521 |
Synonym |
---|
medrosol |
methylprednisolone suleptanate |
promedrol |
u-67590a |
sodium 2-[(8-{[(6alpha,11beta)-11,17-dihydroxy-6-methyl-3,20-dioxopregna-1,4-dien-21-yl]oxy}-8-oxooctanoyl)(methyl)amino]ethanesulfonate |
90350-40-6 |
methylprednisolone suleptanate (usan/inn) |
D05002 |
methylprednisolone suleptanate sodium salt |
methylprednisolone suleptanate [usan:inn] |
methylprednisolone 21-(8-(methyl-(2-sulfoethyl)amino)-1,8-dioxooctanoate) |
suleptanato de methilprednisolona [spanish] |
methylprednisoloni suleptanas [latin] |
pnu 67590a |
suleptanate de methylprednisolone [french] |
u-67,590a |
7-(methyl(2-sulfoethyl)carbamoyl)heptanoic acid, c-21-ester with 11beta,17,21-trihydroxy-6alpha-methylpregna-1,4-diene-3,20-dione, monosodium salt |
u 67590a |
pnu-67590a |
pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-((8-(methyl(2-sulfoethyl)amino)-1,8-dioxooctyl)oxy)-, monosodium salt, (6alpha,11beta)- |
sodium 2-[{8-[(11beta,17-dihydroxy-6alpha-methyl-3,20-dioxopregna-1,4-dien-21-yl)oxy]-8-oxooctanoyl}(methyl)amino]ethanesulfonate |
suleptanato de metilprednisolona |
sodium 2-[{8-[(11beta,17-dihydroxy-6alpha-methyl-3,20-dioxopregna-1,4-dien-21-yl)oxy]-8-oxooctanoyl}(methyl)amino]ethane-1-sulfonate |
methylprednisolone suleptanate sodium |
CHEBI:135864 |
methylprednisoloni suleptanas |
suleptanate de methylprednisolone |
methylprednisolone suleptanate monosodium salt |
g6cs53ncvs , |
suleptanato de methilprednisolona |
unii-g6cs53ncvs |
CHEMBL2106453 |
methylprednisolone suleptanate [inn] |
methylprednisolone suleptanate [usan] |
methylprednisolone suleptanate [who-dd] |
pregna-1,4-diene-3,20-dione, 11,17-dihydroxy-6-methyl-21-((8-(methyl(2-sulfoethyl)amino)-1,8-dioxooctyl)oxy)-, monosodium salt, (6.alpha.,11.beta.)- |
methylprednisolone suleptanate [jan] |
SCHEMBL43507 |
DTXSID7023304 |
Q27278834 |
sodium;2-[[8-[2-[(6s,8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-6,10,13-trimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-8-oxooctanoyl]-methylamino]ethanesulfonate |
Methylprednisolone suleptanate (Promedrol) is being developed by Pharmacia Corp for the treatment of asthma.
Excerpt | Reference | Relevance |
---|---|---|
"Methylprednisolone suleptanate (Promedrol) is a prodrug of methylprednisolone being developed by Pharmacia Corp (formerly Pharmacia & Upjohn) for the treatment of asthma. " | ( Methylprednisolone suleptanate Pharmacia Corp. Paggiaro, P, 2000) | 3.19 |
Excerpt | Reference | Relevance |
---|---|---|
" In addition the differences in the pharmacokinetics for the prodrugs resulted in only a small difference in the relative bioavailability of MP for MP suleptanate (0." | ( A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. Daley-Yates, PT; Parker, TJ; Wood, SA, 1997) | 0.3 |
" The bioavailability of MP was equivalent when based on AUC with a MP suleptanate median 108% of the MP succinate value (90% CI: 102-114%)." | ( Pharmacokinetic and pharmacodynamic assessment of bioavailability for two prodrugs of methylprednisolone. Brooks, CD; Daley-Yates, PT; Gregory, AJ, 1997) | 0.3 |
Excerpt | Relevance | Reference |
---|---|---|
"It was concluded that for the multiple dosage regimen used in patients with acute asthma the systemic exposure to MP following dosing with MP suleptanate is similar to that arising from MP succinate." | ( A comparative population pharmacokinetic analysis for methylprednisolone following multiple dosing of two prodrugs in patients with acute asthma. Daley-Yates, PT; Parker, TJ; Wood, SA, 1997) | 0.3 |
Role | Description |
---|---|
anti-inflammatory agent | Any compound that has anti-inflammatory effects. |
glucocorticoid receptor agonist | An agonist that selectively binds to and activates a glucocorticoid receptor. |
prodrug | A compound that, on administration, must undergo chemical conversion by metabolic processes before becoming the pharmacologically active drug for which it is a prodrug. |
anti-asthmatic drug | A drug used to treat asthma. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
organic sodium salt | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (20.00) | 18.7374 |
1990's | 10 (66.67) | 18.2507 |
2000's | 2 (13.33) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.66) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 4 (26.67%) | 5.53% |
Reviews | 1 (6.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 10 (66.67%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |